Page last updated: 2024-12-11

aurachin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

aurachin B: extracted from myxobacterium, Stigmatella aurantiaca strain Sg a15; MF: C25-H33-N-O2; MW: 379; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aurachin B : An A-type aurachin that is quinoline N-oxide which is substituted by a methyl group at position 2, a hydroxy group at position 3, and a triprenyl group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6439168
CHEMBL ID574536
CHEBI ID131528
SCHEMBL ID3091317
SCHEMBL ID5637270
MeSH IDM0148022

Synonyms (12)

Synonym
aurachin b
CHEMBL574536
CHEBI:131528
2-methyl-1-oxo-4-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1lambda(5)-quinolin-3-ol
108354-12-7
2-methyl-1-oxido-4-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trienyl]quinolin-1-ium-3-ol
3-quinolinol, 2-methyl-4-(3,7,11-trimethyl-2,6,10-dodecatrienyl)-, 1-oxide
aurachin-b
SCHEMBL3091317
SCHEMBL5637270
C21140
Q27225155
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
A-type aurachinAny aurachin in which the farnesyl residue is positioned at C4 of the quinoline core (cf. C-type aurachin, in which the farnesyl residue is positioned at C3). C-type aurachins are converted into A-type aurachins by late stage tailoring reactions.
quinoline N-oxide
olefinic compoundAny organic molecular entity that contains at least one C=C bond.
heteroaryl hydroxy compoundAny organic aromatic compound having one or more hydroxy groups attached to a heteroarene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
aurachin A, B, C and D biosynthesis1026

Bioassays (4)

Assay IDTitleYearJournalArticle
AID436172Inhibition of respiration in bovine heart submitochondrial particles assessed as NADH oxidation2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436174Cytotoxicity against mouse L929 cells after 5 days by MTT assay2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436171Antiplasmodial activity against Plasmodium falciparum D6 clone after 48 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
AID436170Antiplasmodial activity against Plasmodium falciparum W2 after 48 hrs2008Journal of natural products, Nov, Volume: 71, Issue:11
Semisynthesis and antiplasmodial activity of the quinoline alkaloid aurachin E.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.04 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]